Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck

Nature Clinical Practice Oncology

Volumn 6, Issue 3, 2009, Pages 132-133

  William Jr , William N ^a   Kim, Edward S ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; METHOTREXATE; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HEAD AND NECK CARCINOMA; HUMAN; HYPOMAGNESEMIA; MULTIPLE CYCLE TREATMENT; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 61849160432     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1321     Document Type: Note

References (8)

1. Licitra L et al. (2008) Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: New options. Ann Oncol 19 (Suppl 7): Vii200-vii203
2. Vermorken JB et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127
3. Kies MS et al. (2006) Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN) [abstract #5520]. ASCO Meeting Abstracts 24: 5520
4. Tishler RB et al. (2008) Cetuximab added to docetaxel, cisplatin, 5-fluorouracil induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study [abstract #6001]. ASCO Meeting Abstracts 26: 6001
5. Kim ES et al. (2007) Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract #6013]. ASCO Meeting Abstracts 25: 6013
6. Ciardiello F and Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174
7. Vermorken JB et al. (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171-2177
8. Bonner JA et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 567-578